Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice.

Sara McEntee, Yifei Liu, Tahar Mahmoudi, Kathryn Oliver, Chad Cadwell

Current pharmaceutical design 2023

filter terms:

The treatment options for hepatitis C have undergone noteworthy advancements since direct-acting antivirals (DAAs) were introduced. The selection of a DAA therapy depends on the patient's genotype, treatment history, concomitant comorbidities, and concurrent medications. Pharmacists have a pivotal role in providing clarification and recommendations in selecting appropriate, individualized DAAs for patients. This commentary aims to (1) provide an overview of DAAs on the market for hepatitis C, and (2) describe the implication for the care of patients with hepatitis C in a community pharmacy. Community pharmacists can establish a workflow to recommend appropriate DAA therapy, identify drug interactions, and improve medication adherence and compliance with lab appointments. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Sara McEntee, Yifei Liu, Tahar Mahmoudi, Kathryn Oliver, Chad Cadwell. Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice. Current pharmaceutical design. 2023;29(25):1967-1970